<DOC>
	<DOC>NCT00237900</DOC>
	<brief_summary>To assess safety, efficacy and explorative objectives of gefitinib in combination with chemoradiation in resectable gastric cancer</brief_summary>
	<brief_title>Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologicallyconfirmed intestinal GC (T2T4) Local or locally advanced stage II or stage III gastric cancer of an upper part of the stomach or GE junction Lymph node positive or negative Metastasis negative Resection with curative intent (R0, D2) Chemo and radiotherapy na√Øve Measurable lesion according RECIST Written informed consent Aged below 45 or over 70 Prior gastric surgery Active ILD</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>